Sex- and Obesity-specific Association of Aromatase (CYP19A1) Gene Variant with Apolipoprotein B and Hypertension

Archives of Medical Research

Volumn 46, Issue 7, 2015, Pages 564-571

  Coban, Neslihan ^a   Onat, Altan ^a   Guclu Geyik, Filiz ^a   Can, Gunay ^a   Erginel Unaltuna, Nihan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Apolipoprotein B; CYP19A1 polymorphism; Insulin resistance; Sex disparity; TARF study

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; AROMATASE; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; CYP19A1 PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COHORT ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; OBESITY; POSTMENOPAUSE; PREMENOPAUSE; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; BLOOD; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; GENETICS; MIDDLE AGED; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; TURKEY; YOUNG ADULT;

ADULT; APOLIPOPROTEINS B; AROMATASE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; SEX FACTORS; TURKEY; YOUNG ADULT;

EID: 84946085645     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2015.09.004     Document Type: Article

References (41)

1. Barrett-Conner E., Bush T.L. Estrogen and coronary heart disease in women. JAMA 1991, 265:1861-1867.
2. Sasano H., Harada N. Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr Rev 1998, 19:593-607.
3. Means G.D., Mahendroo M.S., Corbin C.J., et al. Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J Biol Chem 1989, 264:19385-19391.
4. Sebastian S., Bulun S.E. A highly complex organization of the regulatory region of the human CYP19 (aromatase) gene revealed by the human genome project. J Clin Endocrinol Metab 2001, 86:4600-4602.
5. Jones M.E., Thorburn A.W., Britt K.L., et al. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc Natl Acad Sci U S A 2000, 97:12735-12740.
6. Meyre D., Lecoeur C., Delplanque J., et al. A genome-wide scan for childhood obesity-associated traits in French families shows significant linkage on chromosome 6q22.31-q23.2. Diabetes 2004, 53:803-811.
7. Martin L.J., Cianflone K., Zakarian R., et al. Bivariate linkage between acylation-stimulating protein and BMI and high-density lipoproteins. Obes Res 2004, 12:669-678.
8. Chagnon Y.C., Borecki I.B., Perusse L., et al. Genome-wide search for genes related to the fat-free body mass in the Quebec family study. Metabolism 2000, 49:203-207.
9. Peter I., Shearman A.M., Zucker D.R., et al. Variation in estrogen-related genes and cross-sectional and longitudinal blood pressure in the Framingham Heart Study. J Hypertens 2005, 23:2193-2200.
10. Ramirez-Lorca R., Grilo A., Martinez-Larrad M.T., et al. Sex and body mass index specific regulation of blood pressure by CYP19A1 gene variants. Hypertension 2007, 50:884-890.
11. Tsuchiya N., Wang L., Suzuki H., et al. Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 2006, 24:1982-1989.
12. Haiman C.A., Dossus L., Setiawan V.W., et al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 2007, 67:1893-1897.
13. Bell D.W., Kim S.H., Godwin A.K., et al. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer 2007, 121:2661-2667.
14. Letonja M., Peterlin B., Bregar D., et al. Are the T/C polymorphism of the CYP17 gene and the tetranucleotide repeat (TTTA) polymorphism of the CYP19 gene genetic markers for premature coronary artery disease in Caucasians?. Folia Biol (Praha) 2005, 51:76-81.
15. Shimodaira M., Nakayama T., Sato N., et al. Association study of aromatase gene (CYP19A1) in essential hypertension. Int J Med Sci 2008, 5:29-35.
16. Baghaei F., Rosmond R., Westberg L., et al. The cyp19 gene and associations with androgens and abdominal obesity in premenopausal women. Obes Res 2003, 11:578-585.
17. Baghaei F., Rosmond R., Westberg L., et al. The lean woman. Obes Res 2002, 10:115-121.
18. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001, 156:1-10.
19. Genuth S., Alberti K.G., Bennett P., et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26:3160-3167.
20. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
21. Grundy S.M., Brewer H.B., Cleeman J.I., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
22. Onat A., Uyarel H., Hergenc G., et al. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2007, 191:182-190.
23. Simpson E.R., Mahendroo M.S., Means G.D., et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994, 15:342-355.
24. Ziv-Gal A., Gallicchio L., Miller S.R., et al. A genetic polymorphism in the CYP19A1 gene and the risk of hypertension among midlife women. Maturitas 2012, 71:70-75.
25. Onat A., Can G., Hergenç G., et al. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension, diabetes, independent of markers of central obesity and inflammation. Int J Obes 2007, 31:1119-1125.
26. Onat A., Can G., Örnek E., et al. Increased apolipoprotein A-I levels mediate the development of prehypertension among Turks. Anadolu Kardiyol Derg 2013, 13:306-314.
27. Paradisi G., Steinberg H.O., Hempfling A., et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001, 103:1410-1415.
28. Shaw L.J., Bairey Merz C.N., Azziz R., et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008, 93:1276-1284.
29. Ding E.L., Song Y., Malik V.S., et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006, 295:1288-1299.
30. Pellegrini M., Pallottini V., Marin R., et al. Role of the sex hormone estrogen in the prevention of lipid disorder. Curr Med Chem 2014, 21:2734-2742.
31. Pineda B., Garcia-Perez M.A., Cano A., et al. Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects. PLoS One 2013, 8e:53902.
32. Colomer R., Monzo M., Tusquets I., et al. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 2008, 14:811-816.
33. Gennari L., Masi L., Merlotti D., et al. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab 2004, 89:2803-2810.
34. Haiman C.A., Hankinson S.E., Spiegelman D., et al. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 2000, 87:204-210.
35. Tworoger S.S., Chubak J., Aiello E.J., et al. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004, 13:94-101.
36. Hammoud A.O., Griffin J., Meikle A.W., et al. Association of aromatase (TTTAn) repeat polymorphism length and the relationship between obesity and decreased sperm concentration. Hum Reprod 2010, 12:3146-3151.
37. Hao C.F., Zhang N., Qu Q., et al. Evaluation of the association between the CYP19 tetranucleotide (TTTA)n polymorphism and polycystic ovarian syndrome(PCOS) in Han Chinese women. Neuro Endocrinol Lett 2010, 31:370-374.
38. Onat A., Hergenç G., Ayhan E., et al. Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor among Turks. Diabet Med 2009, 26:981-988.
39. Onat A., Can G. Enhanced pro-inflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharm Des 2014, 20:575-584.
40. Onat A., Can G., Örnek E., et al. Obesity, hypertriglyceridemia, lipoprotein(a) and apolipoprotein A-I determine cardiometabolic risk. Eur J Clin Invest 2013, 43:1129-1139.
41. Onat A., Can G., Ciçek G., et al. Predictive value of serum apolipoprotein B/LDL-cholesterol ratio in cardiometabolic risk: population-based cohort study. Clin Biochem 2010, 43:1381-1386.